ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

Why Carcinoma, Non-Small-Cell Lung is on this study

  • ClinicalTrials.gov files the study under Carcinoma, Non-Small-Cell Lung.
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Carcinoma, Non-Small-Cell Lung.
6 links0 made here, not in the record4 judgments1 judge (the rules as one: Rule based)38 record changes seen
Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05642195Evaluation of a CancerLysate Vaccine andMontanide (RegisteredTrademark) ISA-51 VG Withor Without the IL-15Super-Agonist N-803 asAdjuvant Therapy for PD-L1National Cancer Institute (NCIPhase 1/Phase 2 · suspendedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 25 · ClinicalTrials.gov record · Version of 2026-09-25Sep 28 · ClinicalTrials.gov record · Version of 2026-09-28Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Sep 30 · ClinicalTrials.gov record · Version of 2026-09-30Oct 1 · ClinicalTrials.gov record · Version of 2026-10-01Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 6 · ClinicalTrials.gov record · Version of 2026-10-06Oct 7 · ClinicalTrials.gov record · Version of 2026-10-07Oct 8 · ClinicalTrials.gov record · Version of 2026-10-08Oct 9 · ClinicalTrials.gov record · Version of 2026-10-09Oct 13 · ClinicalTrials.gov record · Version of 2026-10-13Oct 14 · ClinicalTrials.gov record · Version of 2026-10-14Oct 15 · ClinicalTrials.gov record · Version of 2026-10-15Oct 16 · ClinicalTrials.gov record · Version of 2026-10-16Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Oct 20 · ClinicalTrials.gov record · Version of 2026-10-20Oct 21 · ClinicalTrials.gov record · Version of 2026-10-21Oct 22 · ClinicalTrials.gov record · Version of 2026-10-22Oct 23 · ClinicalTrials.gov record · Version of 2026-10-23Oct 26 · ClinicalTrials.gov record · Version of 2026-10-26Oct 27 · ClinicalTrials.gov record · Version of 2026-10-27Oct 28 · ClinicalTrials.gov record · Version of 2026-10-28Oct 29 · ClinicalTrials.gov record · Version of 2026-10-29Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Nov 3 · ClinicalTrials.gov record · Version of 2026-11-03Nov 4 · ClinicalTrials.gov record · Version of 2026-11-04Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Nov 9 · ClinicalTrials.gov record · Version of 2026-11-09Nov 10 · ClinicalTrials.gov record · Version of 2026-11-10Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 13 · ClinicalTrials.gov record · Version of 2026-11-13Nov 16 · ClinicalTrials.gov record · Version of 2026-11-16Nov 17 · ClinicalTrials.gov record · Version of 2026-11-17Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Nov 19 · ClinicalTrials.gov record · Version of 2026-11-19Version of 2026-11-19CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionCarcinomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Neoplasm, ResidualThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSMontanide ISA 51 VGEntry “Montanide (Registered Trademar…›As of now · Rule based · BackgroundBackgroundINT032540Entry “H1299 Cell Lysates”, read by o…›As of now · Rule based · BackgroundBackgroundNogapendekin alfa inbakiceptEntry “N-803”, read by our name rule›As of now · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
38 versions of the record seen on ClinicalTrials.gov, Sep 25–Nov 19 · changes seen, not judgments
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent
As of nowMontanide ISA 51 VGRule based · role ruleBackgroundCurrent
As of nowINT032540Rule based · role ruleBackgroundCurrent
As of nowNogapendekin alfa inbakiceptRule based · role ruleTestedCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.